Khat - Imfinzi (Durvalumab) Interaction
Herbal: Khat
Also Known As: Catha edulis, Abessinischer Tea, Abyssinian Tea, Arabian-Tea, Chaat, Chat, Gat, Ghat, Hagigat, Kafta, Kat, Kathine, Kus es Salahin, Miraa, Qaad, Qat, Qut, Radaee, Somali Tea, Tchaad, Thé Abyssin, Thé Arabe, Thé Somalien, Tohai, Tohat, Tschat
Drug: Durvalumab
Brand names:
Imfinzi
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
May 25, 2025
Interaction Details
There were no interactions found between Durvalumab and Khat. This does not mean the potential for an interaction does not exist, however. There is often a lack of studies and data surrounding traditional medicine, especially concerning drug interactions, so it is important to always consult your provider before making any changes to your medication regimen.
Khat Overview
Khat (Catha edulis) is a plant that is native to East Africa and the Arabian Peninsula. The leaves and shoots of the plant contain a stimulant compound called cathinone, which is structurally similar to amphetamine and has a stimulant effect on the central nervous system.
Khat is traditionally chewed or made into a tea to produce a feeling of increased energy, alertness, and euphoria. It is also sometimes smoked or used as a nasal decongestant.
Khat use has been associated with a number of negative health effects, including increased heart rate and blood pressure, anxiety, insomnia, and addiction. It can also cause digestive problems, mouth sores, and weight loss. Due to the potential dangers of using khat, it is classified as a controlled substance in many countries, including the United States, where it is illegal to sell, possess, or use the plant or its products.
Durvalumab Overview
-
Durvalumab is used alone to treat non-small cell lung cancer (NSCLC) that spread to nearby tissues and cannot be removed by surgery but has not worsened after being treated with other chemotherapy medications and radiation treatments. It is also used in combination with tremelimumab-actl (Imjudo) and platinum-based chemotherapy to treat a certain type of NSCLC that has spread throughout the lungs and to other parts of the body. Durvalumab injection is also used in combination with chemotherapy agents to treat extensive-stage small cell lung cancer (ES-SCLC) in adults whose cancer has spread throughout the lungs and to other parts of the body. It is also used in combination with chemotherapy agents to treat biliary tract cancer (BTC; cancer in the organs and ducts that make and store bile, the liquid made by the liver) in adults whose cancer has spread to nearby tissues or to other parts of the body. Durvalumab is also used in combination with tremelimumab-actl to treat hepatocellular carcinoma (HCC; a type of liver cancer) that cannot be treated with surgery. Durvalumab injection is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.
Khat - More Interactions
Khat interacts with 401 drugs
Interaction Rating Key
These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.
| Major | The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur. |
| Moderate | Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur. |
| Minor | Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction. |
| Unknown | No interactions have been reported or no interaction data is currently available. |
Return to the main supplement interaction checker page
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Drug descriptions are provided by MedlinePlus.
Ask A Pharmacist About Your Herbal Questions!
Dr. Brian Staiger, PharmD
In addition to being a clinical pharmacist specializing in pharmacotherapy, Dr. Brian Staiger is a registered herbalist through the American Herbalist Guild. He has combined his passion for pharmacy practice with the study of medical ethnobotany to improve patient care. Feel free to reach out about any of your herbal or medication questions!
Ask A Pharmacist